{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:55:06Z","timestamp":1792061706088,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":1143,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chinese Medical Sciences Journal"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.24920\/004137","type":"journal-article","created":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T22:16:52Z","timestamp":1673821012000},"page":"49-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Medical Treatment of Primary Aldosteronism"],"prefix":"10.1016","volume":"38","author":[{"given":"Ying-Jie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.24920\/004137_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Internal Med"},{"key":"10.24920\/004137_bib2","article-title":"Primary aldosteronism","volume":"377","author":"Choy","year":"2022","journal-title":"BMJ (Clinical research ed)"},{"key":"10.24920\/004137_bib3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41574-020-0382-4","article-title":"Pathogenesis and treatment of primary aldosteronism","volume":"16","author":"Zennaro","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.24920\/004137_bib4","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes & endocrinology"},{"key":"10.24920\/004137_bib5","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.jacc.2019.09.057","article-title":"Primary aldosteronism: Jacc state-of-the-art review","volume":"74","author":"Rossi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.24920\/004137_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.molmed.2020.05.005","article-title":"Genetic and genomic mechanisms of primary aldosteronism","volume":"26","author":"Fernandes-Rosa","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.24920\/004137_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.927669","article-title":"Pathogenesis of primary aldosteronism: impact on clinical outcome","volume":"13","author":"Santana","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.24920\/004137_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1210\/jc.2015-3284","article-title":"Clinical and steroidogenic characteristics of aldosterone-producing adenomas with atpase or cacnald gene mutations","volume":"101","author":"Kitamoto","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.24920\/004137_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimaeric 11 beta-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"key":"10.24920\/004137_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"Clcn2 chloride channel mutations in familial hyperaldosteronism type ii","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat Genet"},{"key":"10.24920\/004137_bib11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science (New York, NY)"},{"key":"10.24920\/004137_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","article-title":"A gain-of-function mutation in the clcn2 chloride channel gene causes primary aldosteronism","volume":"50","author":"Fernandes-Rosa","year":"2018","journal-title":"Nat Genet"},{"key":"10.24920\/004137_bib13","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2018-01004","article-title":"Targeted molecular characterization of aldosterone-producing adenomas in white americans","volume":"103","author":"Nanba","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.24920\/004137_bib14","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.119.14177","article-title":"Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma","volume":"75","author":"De Sousa","year":"2020","journal-title":"Hypertension"},{"key":"10.24920\/004137_bib15","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline cacnald calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"key":"10.24920\/004137_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: Practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"key":"10.24920\/004137_bib17","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1210\/en.2015-2029","article-title":"Cellular pathophysiology of an adrenal adenoma-associated mutant of the plasma membrane ca(2+)-at-pase atp2b3","volume":"157","author":"Tauber","year":"2016","journal-title":"Endocrinology"},{"key":"10.24920\/004137_bib18","doi-asserted-by":"crossref","first-page":"K37","DOI":"10.1530\/EJE-19-0377","article-title":"A somatic mutation in clcn2 identified in a sporadic aldosterone-producing adenoma","volume":"181","author":"Dutta","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.24920\/004137_bib19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.24920\/004137_bib20","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1530\/EJE-19-0215","article-title":"Therapy of endocrine disease: Medical treatment of primary aldosteronism","volume":"181","author":"Lechner","year":"2019","journal-title":"European J Endocrinol"},{"key":"10.24920\/004137_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.861581","article-title":"Benefits of surgical over medical treatment for unilateral primary aldosteronism","volume":"13","author":"Ahmed","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.24920\/004137_bib22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.mcna.2021.06.007","article-title":"Primary hyperaldosteronism: Approach to diagnosis and management","volume":"105","author":"El-Asmar","year":"2021","journal-title":"Med Clin N Am"},{"key":"10.24920\/004137_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013699","article-title":"Influence of different treatment strategies on new-onset atrial fibrillation among patients with primary aldosteronism: a nationwide longitudinal cohort-based study","volume":"9","author":"Pan","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.24920\/004137_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2017-01442","article-title":"Quality of life in primary aldosteronism: A comparative effectiveness study of adrenalectomy and medical treatment","volume":"103","author":"Velema","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.24920\/004137_bib25","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.24920\/004137_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/hr.2015.129","article-title":"Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism","volume":"39","author":"Karashima","year":"2016","journal-title":"Hypertens Res"},{"key":"10.24920\/004137_bib27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: The german conn's registry","volume":"60","author":"Reincke","year":"2012","journal-title":"Hypertension"},{"key":"10.24920\/004137_bib28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism","volume":"50","author":"Catena","year":"2007","journal-title":"Hypertension"},{"key":"10.24920\/004137_bib29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1177\/1470320314549220","article-title":"Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism","volume":"16","author":"Indra","year":"2015","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.24920\/004137_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.24920\/004137_bib31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.24920\/004137_bib32","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J Endocrinol"},{"issue":"31","key":"10.24920\/004137_bib33","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"10.24920\/004137_bib34","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ejhf.888","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"19","author":"Bramlage","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.24920\/004137_bib35","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.24920\/004137_bib36","article-title":"Visualization of calcium channel blockers in human adrenal tissues and their possible effects on steroidogenesis in the patients with primary aldosteronism (pa)","volume":"218","author":"Motomura","year":"2022","journal-title":"J Steroid Biochem"},{"key":"10.24920\/004137_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1530\/JOE-19-0259","article-title":"L- and t-type calcium channels control aldosterone production from human adrenals","volume":"244","author":"Yang","year":"2020","journal-title":"J Endocrinol"},{"key":"10.24920\/004137_bib38","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/en.2013-1944","article-title":"Pharmacology and pathophysiology of mutated kcnj5 found in adrenal aldosterone-producing adenomas","volume":"155","author":"Tauber","year":"2014","journal-title":"Endocrinology"},{"key":"10.24920\/004137_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2020.00260","article-title":"The effects of different calcium channel blockers on aldosterone-producing adenoma cells","volume":"11","author":"Wang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.24920\/004137_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19336950.2020.1761171","article-title":"A de novo cacnald missense mutation in a patient with congenital hyperinsulinism, primary hyperaldosteronism and hypotonia","volume":"14","author":"De Mingo Alemany","year":"2020","journal-title":"Channels (Austin, Tex)"},{"key":"10.24920\/004137_bib41","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","article-title":"Macrolides selectively inhibit mutant kcnj5 potassium channels that cause aldosterone-producing adenoma","volume":"127","author":"Scholl","year":"2017","journal-title":"J Clin Invest"},{"key":"10.24920\/004137_bib42","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/HYPERTENSIONAHA.117.10226","article-title":"Macrolides blunt aldosterone biosynthesis: A proof-of-concept study in kcnj5 mutated adenoma cells ex vivo","volume":"70","author":"Caroccia","year":"2017","journal-title":"Hypertension"},{"key":"10.24920\/004137_bib43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/08037051.2018.1436961","article-title":"Macrolides for kcnj5-mutated aldosterone-producing adenoma (mapa): design of a study for personalized diagnosis of primary aldosteronism","volume":"27","author":"Maiolino","year":"2018","journal-title":"Blood Press"},{"key":"10.24920\/004137_bib44","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.24920\/004137_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.547356","article-title":"Associations between metabolic profiles and target-organ damage in Chinese individuals with primary aldosteronism","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.24920\/004137_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13543776.2021.1965991","article-title":"A patent review of aldosterone synthase inhibitors (2014-present)","volume":"32","author":"Wu","year":"2022","journal-title":"Expert opinion on therapeutic patents"},{"key":"10.24920\/004137_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/bs.vh.2018.10.002","article-title":"Inhibitors of aldosterone synthase","volume":"109","author":"Weldon","year":"2019","journal-title":"Vitam Horm"},{"key":"10.24920\/004137_bib48","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/HJH.0b013e32835d6d49","article-title":"Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism","volume":"31","author":"Amar","year":"2013","journal-title":"J Hypertens"},{"key":"10.24920\/004137_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacological research"},{"key":"10.24920\/004137_bib50","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (cypllb2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"key":"10.24920\/004137_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061332","article-title":"Cul4-ddb1-crbn e3 ubiquitin ligase regulates proteostasis of clc-2 chloride channels: implication for aldosteronism and leukodystrophy","volume":"9","author":"Fu","year":"2020","journal-title":"Cells"},{"key":"10.24920\/004137_bib52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41574-020-0359-3","article-title":"Vitamin d supplementation: A novel therapy for aldosteronism?","volume":"16","author":"Rossi","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.24920\/004137_bib53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cen.14177","article-title":"The effect of vitamin d treatment on clinical and biochemical outcomes of primary aldosteronism","volume":"92","author":"Ismail","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.24920\/004137_bib54","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cmet.2008.10.011","article-title":"Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism","volume":"8","author":"Kumar","year":"2008","journal-title":"Cell metabolism"},{"key":"10.24920\/004137_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.561370","article-title":"Adropin stimulates proliferation and inhibits adrenocortical steroidogenesis in the human adrenal carcinoma (hac15) cell line","volume":"11","author":"Stelcer","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.24920\/004137_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9640103","article-title":"Adrenal (pro)renin receptor expression and serum soluble (pro)renin receptor concentration in primary aldosteronism","volume":"2020","author":"Watanabe","year":"2020","journal-title":"Int J Endocrinol"}],"container-title":["Chinese Medical Sciences Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1001929423000184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1001929423000184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/cmsj.cams.cn\/previewFile?fileName=Advances%20in%20Medical%20Treatment%20of%20Primary%20Aldosteronism&id=90540123&type=pdf&lang=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:34:09Z","timestamp":1792060449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1001929423000184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1001929423000184"],"URL":"https:\/\/doi.org\/10.24920\/004137","relation":{},"ISSN":["1001-9294"],"issn-type":[{"value":"1001-9294","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Medical Treatment of Primary Aldosteronism","name":"articletitle","label":"Article Title"},{"value":"Chinese Medical Sciences Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.24920\/004137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 Chinese Academy Medical Sciences. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}